Guidance

Impact assessment to permit a 0.2 percent increase in the list price of branded medicines supplied by manufactures and suppliers under the statutory scheme from January 2012

Impact assessment to permit a 0.2 percent increase in the list price of branded medicines supplied by manufactures and suppliers under the statutory scheme from January 2012.

Documents

Download Impact Assessment - increase in branded medicine

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk . Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Impact assessment to permit a 0.2 percent increase in the list price of branded medicines supplied by manufactures and suppliers under the statutory scheme from January 2012.

Published 7 December 2011